DZ Bank AG reissued their neutral rating on shares of Fresenius Medical Care AG (NYSE:FMS) in a report published on Friday.

Analyst Recommendations for Fresenius Medical Care AG (NYSE:FMS)

A number of other research analysts also recently commented on the company. Goldman Sachs Group Inc. reiterated a buy rating on shares of Fresenius Medical Care AG in a report on Tuesday, September 13th. Citigroup Inc. upgraded Fresenius Medical Care AG from a neutral rating to a buy rating in a report on Tuesday, September 6th. Berenberg Bank reiterated a buy rating on shares of Fresenius Medical Care AG in a report on Tuesday, August 9th. Jefferies Group upgraded Fresenius Medical Care AG from an underperform rating to a hold rating in a report on Friday, July 8th. Finally, Royal Bank Of Canada reiterated a hold rating on shares of Fresenius Medical Care AG in a report on Tuesday, May 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $42.50.

Fresenius Medical Care AG (NYSE:FMS) opened at 44.03 on Friday. The stock has a market capitalization of $26.92 billion, a PE ratio of 24.41 and a beta of 0.53. The company’s 50-day moving average price is $45.27 and its 200 day moving average price is $43.75. Fresenius Medical Care AG has a 12 month low of $38.11 and a 12 month high of $47.52.

Fresenius Medical Care AG (NYSE:FMS) last released its quarterly earnings data on Tuesday, August 2nd. The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.04. Fresenius Medical Care AG had a return on equity of 9.66% and a net margin of 6.40%. The business had revenue of $4.42 billion for the quarter, compared to the consensus estimate of $4.54 billion. On average, analysts forecast that Fresenius Medical Care AG will post $2.01 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC purchased a new position in Fresenius Medical Care AG during the second quarter valued at $235,000. Stifel Financial Corp increased its position in Fresenius Medical Care AG by 56.5% in the second quarter. Stifel Financial Corp now owns 12,344 shares of the company’s stock valued at $539,000 after buying an additional 4,456 shares during the last quarter. FDx Advisors Inc. increased its position in Fresenius Medical Care AG by 0.9% in the second quarter. FDx Advisors Inc. now owns 5,597 shares of the company’s stock valued at $244,000 after buying an additional 51 shares during the last quarter. A.R.T. Advisors LLC purchased a new position in Fresenius Medical Care AG during the second quarter valued at $599,000. Finally, Eagle Global Advisors LLC increased its position in Fresenius Medical Care AG by 3.9% in the second quarter. Eagle Global Advisors LLC now owns 66,100 shares of the company’s stock valued at $2,880,000 after buying an additional 2,500 shares during the last quarter. 2.33% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG Company Profile

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

5 Day Chart for NYSE:FMS

Receive News & Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related companies with MarketBeat.com's FREE daily email newsletter.